Investors

 

Key to long-term value: discipline, execution and consistent communication.

Print pageEmail pageRSS feedsShare page

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
05/24/16ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jennifer L. Herron as executive vice president, chief commercial officer, effective May 31, 2016. She will report to ARIAD’s president and chief executive officer, Paris Panayiotopoulos. Ms. Herron will succeed Martin J. Duvall, who has made significant contributions to ARIAD since first joining the company in 2011. Mr. D... 
Printer Friendly Version
05/19/16ARIAD Announces Pricing and Reimbursement for Iclusig in France
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 19, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig® (ponatinib) have now concluded. As a result, ARIAD will record net product revenue related to cumulative shipments in France of approximately $25 million in the second quarter of 2016. Iclusig has b... 
Printer Friendly Version
05/18/16ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting
~Oral Presentation of Clinical Data from ALTA Pivotal Trial on Monday, June 6, 2016 ~ ASCO Presentation to Include Approximately 3 Months of Additional Follow-up Compared to Abstract ~Investor and Analyst Briefing to be Held at ASCO on Monday, June 6 at 7 a.m. CT CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on brigatinib, its invest... 
Printer Friendly Version
05/10/16ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
~Recorded Net Product Revenue of $33.6 million for the first quarter of 2016; growth of 41% from prior year ~Provides guidance for 2016, including strengthened year-end cash position, following announced Incyte transaction: Global product and royalty revenue of $170 million to $180 million R&D expense of $175 million to $180 million SG&A expense of $120 million to $125 million ... 
Printer Friendly Version
05/09/16Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potential Milestones on Future Indications for Iclusig WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals... 
Printer Friendly Version
04/26/16ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2016 financial results on Tuesday, May 10, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visit... 
Printer Friendly Version
04/19/16ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research
First Presentation of Preclinical Data Supports Upcoming Clinical Testing in Non-Small Cell Lung Cancer Patients with EGFR and HER2 Exon 20 Mutations CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)--Apr. 19, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of comprehensive preclinical studies on its investigational tyrosine kinase inhibitor (TKI), AP32788, at the American Association for Cancer Research ... 
Printer Friendly Version
04/15/16ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
GENEVA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib, in patients with advanced malignancies, including anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC), from an ongoing Phase 1/2 trial. This report includes updated data on the brigatinib safety profile and pharmacokin... 
Printer Friendly Version
04/11/16ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a randomized, first-line Phase 3 clinical trial of brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, in adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously been treated with an ALK inhibitor. The ALTA 1L (ALK in Lung Can... 
Printer Friendly Version
03/29/16ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
Approximately 25 Percent of its Headquarter Positions to be Impacted CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 29, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 25 percent of its headquarter positions. The reduction includes approximately 90 positions in the U.S. and Europe. No customer-facing positions within ARIAD’s commercial or medical affairs organizations are included in this action. ... 
Printer Friendly Version
03/22/16ARIAD Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Financial Officer, Manmeet S. Soni. The award was approved by the Compensation Committee and ratified by the full Board of Directors on March 8, 2016, as an inducement material to Mr. Soni’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). The awar... 
Printer Friendly Version
03/11/16ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Manmeet S. Soni, 38, as executive vice president, chief financial officer and treasurer, effective March 21, 2016. He will report to Paris Panayiotopoulos, president and chief executive officer of ARIAD. Mr. Soni will succeed Edward M. Fitzgerald, who has made significant contributions to the company as ARIAD’s chief fin... 
Printer Friendly Version
02/29/16ARIAD to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business at two upcoming investor conferences: The Cowen and Company 36th Annual Health Care Conference being held in Boston on Wednesday, March 9, at 8:40 a.m. (ET) The Barclays Global Healthca... 
Printer Friendly Version
02/23/16ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
Iclusig Net Product Revenue Guidance for 2016 in the Range of $190 Million to $200 Million Filing for U.S. Marketing Approval of Brigatinib Expected This Year Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 23, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2015 and issued 2016 product reven... 
Printer Friendly Version
02/10/16ARIAD to Present at the RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 24, at 4:35 p.m. (ET). The ARIAD presentation at the RBC Capital Markets Healthcare Conference ... 
Printer Friendly Version
02/02/16ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 23, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast... 
Printer Friendly Version
02/01/16ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
Internally Discovered Product Candidate Designed to Address Unmet Need in Non-Small Cell Lung Cancer Patients with Specific EGFR and HER2 Kinase Mutations CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AP32788, a tyrosine kinase inhibitor (T... 
Printer Friendly Version
01/15/16ARIAD Reports Inducement Grant to New Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Executive Officer, Paris Panayiotopoulos. The award was approved by the Compensation Committee and ratified by the full Board of Directors on December 16, 2015, as an inducement material to Mr. Panayiotopoulos’ entering into employment with the Company in accordance with NASDAQ Listing Rule ... 
Printer Friendly Version
01/11/16ARIAD Announces Termination of Shareholder Rights Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its Board of Directors has unanimously approved the termination of the Company’s Section 382 Rights Agreement, or the Rights Plan, originally adopted on October 31, 2013, effective immediately. The Rights Plan and the associated rights expired at 5:00 p.m. EST on January 8, 2016, and will be of no further force or effect. ARIAD shareho... 
Printer Friendly Version
01/10/16ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the election of Alexander J. Denner, Ph.D., as chairman of its board of directors in a unanimous vote effective January 8, 2016. Dr. Denner joined the ARIAD Board of Directors in February 2014 and most recently led the Board’s search committee to select the Company’s new CEO Paris Panayiotopoulos. This Smart News Release features multime... 
Printer Friendly Version
01/08/16ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib
Submission based on Phase 2 trial in Japanese patients with refractory chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices A... 
Printer Friendly Version